Molecular Partners AG

Discover how Molecular Partners AG’s new Switch‑DARPin MP0632 and DLL3‑targeted Radio‑DARPin MP0712 breakthrough at AACR 2026 could reshape cancer therapy and spark investor confidence.

Molecular Partners AG, a Swiss biotech company, has made significant strides in developing innovative therapies, with promising clinical trial results and strategic financial moves that position it for long-term success.

Molecular Partners AG presented new preclinical data at AACR 2025, showcasing advancements in its Radio-DARPin and Switch-DARPin programs, particularly in oncology, with clinical trials set to commence in 2025.